TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.

Also called NCT01090037

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 892 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01090037
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Hong Kong SAR China, Japan, Malaysia, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01090037. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
Condition
Chronic Renal Failure
Condition
Glomerular Disease
Condition
Nephrosclerosis
Intervention (Drug)
TRK-100STP high dose
Intervention (Drug)
TRK-100STP low dose
Intervention (Drug)
Placebo
Lead sponsor
Toray Industries, Inc (class: industry)
Collaborator
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01090037
Content hash
60fd20a817b94b3a8f2ba808bb2a22d6999548372ccdd9378e17fd3e4130acd1